New antibiotic compounds for drug-resistant tuberculosis
Development of 1,2,4-Triazolyl Compounds and their derivatives as a New Treatment for Tuberculosis
['FUNDING_R01'] · WASHINGTON UNIVERSITY · NIH-11159804
New 1,2,4-triazole antibiotic compounds aimed at treating people with drug-resistant tuberculosis.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-11159804 on ClinicalTrials.gov |
What this research studies
Researchers at Washington University are developing a new class of TB drugs called nitro 1,2,4-triazoles that have shown activity against TB strains resistant to isoniazid, rifampicin, and moxifloxacin. The team makes and tests many related compounds in the lab, examines how the drugs kill TB bacteria, and selects resistant bacterial mutants to understand possible resistance pathways. They use bacterial cultures, genetic sequencing, and preclinical models to check effectiveness and safety before any human testing. Their goal is to create a medicine that works differently than current antibiotics to help patients whose infections no longer respond to existing treatments.
Who could benefit from this research
Good fit: Adults with active, drug-resistant pulmonary tuberculosis would be the most likely candidates for future clinical testing.
Not a fit: People with latent TB, infections easily cured by standard antibiotics, or conditions unrelated to TB would likely not benefit from this research in the near term.
Why it matters
Potential benefit: Could lead to a new medicine that treats tuberculosis that no longer responds to current antibiotics.
How similar studies have performed: Related nitro-based TB drugs such as pretomanid have helped treat drug-resistant TB, but this 1,2,4-triazole series is a new chemical approach that still needs preclinical and clinical testing.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: STALLINGS, CHRISTINA LEIGH — WASHINGTON UNIVERSITY
- Study coordinator: STALLINGS, CHRISTINA LEIGH
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.